In this review, we focus on describing the emerging evidence for GDF15, VEGF, TGF-β1, HSP90, HMGB1, and S100A9 as candidate biomarkers across renal and bladder cancers—highlighting their biological rationales, analytical performance characteristics, and prospective roles in clinical practice. Here, TGFB1 is linked to urinary bladder cancer.